Drug
phase II
phase II is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
3
75%
Ph not_applicable
1
25%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting2
Not yet recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (75.0%)
N/A1 (25.0%)
Trials by Status
not_yet_recruiting125%
recruiting250%
unknown125%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruitingphase_1
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
NCT07446725
recruitingphase_1
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055
recruitingnot_applicable
Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer
NCT04679454
unknownphase_1
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
NCT05429905
Clinical Trials (4)
Showing 4 of 4 trials
NCT07446725Phase 1
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
NCT06464055Phase 1
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT04679454Not Applicable
Single Fraction Preoperative Radiotherapy for Early Stage Breast Cancer
NCT05429905Phase 1
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4